Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics

NDT Plus

Volumn 1, Issue SUPPL.1, 2008, Pages

  Cunningham, John ^a   Floege, Jürgen ^b   London, Gérard ^c   Rodriguez, Mariano ^d   Shanahan, Catherine M ^e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Manhes Hospital   (France)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cinacalcet; Morbidity; Mortality; Outcomes; Secondary hyperparathyroidism

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PHOSPHATE BINDING AGENT; PLACEBO; R 568; UNCLASSIFIED DRUG; VITAMIN D;

ADD ON THERAPY; ARTERY COMPLIANCE; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG RECEPTOR BINDING; FRACTURE; HOSPITALIZATION; HUMAN; MINERAL METABOLISM; MONOTHERAPY; OUTCOME ASSESSMENT; PARATHYROID GLAND; PARATHYROIDECTOMY; PRIORITY JOURNAL; PULSE WAVE; QUALITY OF LIFE; RECEPTOR SENSITIVITY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SKELETON; UREMIA;

EID: 39349094529     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm042     Document Type: Conference Paper

References (51)

1. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol 2005; 288: F253-F264
2. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-2105
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
4. Tokuyama T, Ikeda T, Sato K, Mimura O, Morita A, Tabata T. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients. Am J Kid Dis 2002; 39: 291-296
5. Floege J. When man turns to stone: Extraosseous calcification in uremic patients. Kidney Int 2004; 65: 2447-2462
6. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: New insights into an old phenomenon. Hypertension 2006; 47: 1027-1034
7. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399
8. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kid Dis 2004; 44: 672-679
9. Tejwani NC, Schachter AK, Immerman I, Achan P. Renal osteodystrophy. J Am Acad of Orthop Surg 2006; 14: 303-311
10. London GM, Guerin AP, Marchais SJ et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-608
11. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769
12. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
13. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
14. Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16: 210-218
15. Kim J, Dylan M, Doan Q et al. Association of elevated serum parathyroid hormone (PTH) and calcium with hip, vertebral, or pelvic fracture in hemodialysis patients [Abstract S026]. Presented at: ERA-EDTA Congress, 15-18 May 2004, Lisbon, Portugal
16. Gorodetskaya I, Zenios S. McCulloch CE et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68: 2801-2808
17. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
18. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299
19. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867
20. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
21. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
22. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
23. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555
24. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-1860
25. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries: Prognostic significance for end-stage renal disease patients. Hypertension 2005; 45: 592-596
26. Rodriguez-Garcia K Naves M, Cannata-Andia J. Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol 2005; 18: 458-463
27. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 1998; 8: 357-375
28. Ishimura E, Taniwaki H, Tabata T et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 2005; 45: 859-865
29. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 2004; 13: 63-70
30. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res 2005; 96: 717-722
31. Shanahan CM, Cary NP, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999; 100: 168-2176
32. Wada T, McKee MD, Steitz S. Giachelli CM. Calcification of vascular smooth muscle cell cultures: Inhibition by osteoponim. Circ Res 1999; 84: 166-178
33. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
34. 2 -Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366
35. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-494
36. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-740
37. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804
38. 3 but not cinacalcet HCl (Sensiparg®Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370-1377
39. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 2005; 27: 1725-1751
40. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
41. Lindberg IS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
42. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254
43. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
44. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
45. Chertow GM, Block G, Correa-Rotter R et al. EValuation Of Cinacalcet HCl Therapy to Lower Cardio Vascular Events (EVOLVE) Trial [PUB359]. Presented at: Renal Week, 14-19 November 2006, San Diego, CA
46. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl an cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 2005; 68: 1793-1800
47. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenual paradxyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476
48. Urena P, Bernard-Poenaru O, Ostertag A et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2325-2331
49. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density inpatients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237
50. Kurella M, Luan J, Yaffe K et al. Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. Kidney Int 2004; 66: 2161-2367
51. Perlman RL, Finkelstein FO, Liu L et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal. Research Institute-CKD study. Am J Kidney Dis 2005; 45: 658-666